A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
16actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-26 | actual | When the study began enrolling |
| Primary completion | 2026-06-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-05 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-722
- Drug: Upadacitinib
Primary outcomes
what the primary-completion date above is the date OFMaximum observed plasma concentration at steady state (Cmax,ss) of ABBV-722
measured Up to Day 6 in Period 2 and Up to Day 17 in Period 3
Time to maximum observed plasma concentration (Tmax) of ABBV-722
measured Up to Day 6 in Period 2 and Up to Day 17 in Period 3
Area under curve over the dosing interval at steady state (AUCtau,ss) of ABBV-722
measured Up to Day 6 in Period 2 and Up to Day 17 in Period 3
Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of ABBV-722
measured Up to Day 6 in Period 2 and Up to Day 17 in Period 3
Maximum observed plasma concentration at steady state (Cmax,ss) of Upadacitinib
measured Up to Day 7 in Period 1 and Up to Day 17 in Period 3
Time to maximum observed plasma concentration (Tmax) of Upadacitinib
measured Up to Day 7 in Period 1 and Up to Day 17 in Period 3
Area under curve over the dosing interval at steady state (AUCtau,ss) of Upadacitinib
measured Up to Day 7 in Period 1 and Up to Day 17 in Period 3
Observed plasma concentration at the end of the dosing interval at steady state (Ctrough,ss) of Upadacitinib
measured Up to Day 7 in Period 1 and Up to Day 17 in Period 3
Number of Participants with Adverse Events (AEs)
measured Approximately up to 91 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed